Study guide
5.1 Aortic Dissection, Aortic Aneurysms & Hypertensive Crises
AACN Cardiac Medicine Certification CMC
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Overview and the CMC Test Plan
1.1 CMC Exam Format, Eligibility, Fees & Scoring 1.2 The CMC Test Plan: Four Domains and How to Study Them
2 Chapter 2: Acute Coronary Syndromes and Ischemic Heart Disease
2.1 Pathophysiology & Classification of Acute Coronary Syndromes 2.2 12-Lead ECG Localization & Cardiac Biomarker Trajectories 2.3 Acute Reperfusion Strategies & Nursing Management 2.4 Complications of Acute Myocardial Infarction 2.5 Chronic Coronary Disease, Hyperlipidemia and Lipid-Lowering Therapy
3 Chapter 3: Heart Failure, Cardiomyopathies, Pericardial and Valvular Disease
3.1 Acute Decompensated Heart Failure & Staging 3.2 Acute Cardiogenic Pulmonary Edema 3.3 Dilated, Hypertrophic, and Restrictive Cardiomyopathies 3.4 Acute Pericarditis, Cardiac Tamponade & Constrictive Pericarditis 3.5 Infective Endocarditis, Myocarditis and Rheumatic Heart Disease 3.6 Valvular Heart Disease: Stenosis & Regurgitation 3.7 Syncope: Cardiac Versus Non-Cardiac Causes and Workup
4 Chapter 4: Dysrhythmias, Conduction Disorders and Electrophysiologic Interventions
4.1 Atrial Fibrillation, Atrial Flutter & Supraventricular Tachycardias 4.2 Ventricular Arrhythmias & Cardiac Arrest Management 4.3 Atrioventricular Blocks & Intraventricular Conduction Delays 4.4 Temporary Pacing: Transcutaneous, Transvenous and Epicardial 4.5 Permanent Pacemakers, CRT and Device Troubleshooting 4.6 Implantable and Wearable Cardioverter Defibrillators 4.7 Catheter Ablation and Post-Ablation Nursing Care 4.8 Synchronized Cardioversion and Defibrillation
5 Chapter 5: Vascular Conditions and Vascular Interventions
5.1 Aortic Dissection, Aortic Aneurysms & Hypertensive Crises 5.2 Peripheral Artery Disease & Acute Limb Ischemia 5.3 Acute Venous Thrombosis, DVT and VTE Prophylaxis 5.4 Peripheral and Carotid Angiography and Interventions 5.5 Endovascular Aortic Repair: EVAR and TEVAR 5.6 Catheter-Directed Thrombolysis and Post-Intervention Vascular Complications
6 Chapter 6: Shock States and Mechanical Circulatory Support
6.1 Cardiogenic Shock Pathophysiology, Hemodynamics & Etiologies 6.2 Non-Cardiogenic Shock: Hypovolemic, Distributive and Obstructive 6.3 Multisystem Organ Dysfunction Syndrome 6.4 Intra-Aortic Balloon Pump Therapy & Waveform Optimization 6.5 Percutaneous & Surgical Mechanical Circulatory Support: Impella, VA-ECMO, LVAD
7 Chapter 7: Cardiac Procedures and Structural Heart Interventions
7.1 Diagnostic Cardiac Catheterization & Coronary Angiography Interpretation 7.2 Percutaneous Coronary Intervention: Stents, No-Reflow and Post-PCI Care 7.3 Structural Heart Interventions: TAVR, MitraClip, Pericardiocentesis 7.4 Post-Cardiac Surgery Management (>48 Hours) & Late Complications
8 Chapter 8: Cardiovascular Pharmacology
8.1 Inotropes, Vasopressors & Inodilators 8.2 Vasodilators & Antianginal Agents 8.3 Antiarrhythmic Agents: Vaughan Williams Classes I-IV 8.4 Anticoagulants, Antiplatelets, Thrombolytics & Reversal Agents 8.5 Diuretics and Decongestion Strategies 8.6 Guideline-Directed Medical Therapy for Heart Failure
9 Chapter 9: Non-Cardiovascular Conditions: Pulmonary
9.1 Acute Pulmonary Embolism 9.2 Acute Respiratory Failure and ARDS 9.3 Pleural Space Abnormalities: Pneumothorax, Effusion and Hemothorax 9.4 Pulmonary Hypertension and Right Ventricular Failure 9.5 Sleep-Disordered Breathing in Cardiac Patients
10 Chapter 10: Non-Cardiovascular Conditions: Endocrine, Renal, Hematologic, Neurologic and Behavioral
10.1 Diabetes Mellitus and Glycemic Control in Cardiac Care 10.2 Thyroid and Adrenal Disorders in the Cardiac Patient 10.3 Metabolic Syndrome and Cardiometabolic Risk 10.4 Coagulopathies: Heparin-Induced Thrombocytopenia, DIC and Bleeding Disorders 10.5 Anemia and Transfusion Management in Cardiac Patients 10.6 Acute Ischemic and Hemorrhagic Stroke in the Cardiac Patient 10.7 Acute Kidney Injury and Contrast-Associated Nephropathy 10.8 Chronic Kidney Disease and the Dialysis-Dependent Cardiac Patient 10.9 Electrolyte Imbalances and Dysrhythmia Risk 10.10 Substance Use, Withdrawal and Cardiac Effects 10.11 Non-Cardiac Chest Pain: Differential and Triage 10.12 Non-Cardiovascular Multisystem Complications in Cardiac Patients
11 Chapter 11: Monitoring and Diagnostics
11.1 Pulmonary Artery Catheterization & Hemodynamic Waveform Interpretation 11.2 Arterial Line Monitoring, Continuous Cardiac Output & ScvO2 11.3 Echocardiography, Cardiac MRI & Non-Invasive Cardiac Imaging 11.4 Stress Testing and Myocardial Perfusion Imaging 11.5 Remote Cardiovascular Monitoring and Ambulatory Rhythm Devices 11.6 Laboratory Testing in Cardiac Care 11.7 Arterial Blood Gases and Acid-Base Interpretation 11.8 Pulse Oximetry, Capnography and Chest Radiography
12 Chapter 12: Respiratory, Renal and Multisystem Therapeutic Interventions
12.1 Non-Invasive Ventilation in Cardiac Patients 12.2 Invasive Mechanical Ventilation and Heart-Lung Interactions 12.3 Renal Replacement Therapy: Hemodialysis, CRRT, SCUF and Ultrafiltration 12.4 Targeted Temperature Management After Cardiac Arrest 12.5 Palliative and End-of-Life Care in Advanced Cardiac Disease
5.1 Aortic Dissection, Aortic Aneurysms & Hypertensive Crises
Key Takeaways Explain This Topic AI
Stanford Type A aortic dissections involve the ascending aorta and are surgical emergencies; Stanford Type B dissections involve the descending aorta and are managed medically unless complicated by end-organ malperfusion or rupture.
Anti-impulse therapy requires strict sequencing: IV beta-blockers (Esmolol or Labetalol) MUST be initiated FIRST to lower HR to <60 bpm and SBP to 100-120 mmHg before administering vasodilators to prevent reflex tachycardia and shear stress propagation.
Thoracic and Abdominal Aortic Aneurysms require surgical or endovascular repair when thresholds (≥5.5 cm in men, ≥5.0 cm in women/Marfan, or rapid growth >0.5 cm/6 months) are breached.
Hypertensive Emergency is distinguished from Hypertensive Urgency by the presence of acute target organ damage (encephalopathy, ACS, aortic dissection, acute renal failure).
Standard Hypertensive Emergency management dictates reducing Mean Arterial Pressure by a maximum of 20-25% in the first hour to prevent cerebral and organ ischemia; Aortic Dissection is a critical exception requiring rapid reduction of SBP to <120 mmHg within 20 minutes.
Last updated: August 2026
5.1 Aortic Dissection, Aortic Aneurysms & Hypertensive Crises
Aortic disasters and hypertensive emergencies represent life-threatening vascular crises frequently managed in cardiac intensive care units. Rapid diagnostic identification, precise pharmacological control of aortic shear stress (dP/dt), and an understanding of surgical versus medical thresholds are core competencies evaluated on the AACN CMC examination.
Aortic Dissection: Classifications & Pathophysiology
Aortic dissection originates from a tear in the intimal layer of the aortic wall, allowing pressurized blood to enter the media, creating a false lumen that propagates proximally or distally along the vessel.
Classification Systems
Stanford Classification (Most clinically utilized):
Type A : Involves the ascending aorta (with or without extension into the arch or descending aorta). Accounts for ~65% of cases. Represents a surgical emergency due to risks of retrograde extension causing pericardial tamponade, acute aortic valve disruption, or coronary ostial occlusion.
Type B : Involves exclusively the descending aorta distal to the origin of the left subclavian artery. Typically managed medically in the ICU unless complicated by branch vessel malperfusion, rapid expansion, or rupture.
DeBakey Classification :
Type I : Originates in ascending aorta and propagates distally through the aortic arch and descending aorta.
Type II : Confined strictly to the ascending aorta.
Type III : Confined to the descending thoracic aorta (IIIa: proximal to celiac axis; IIIb: extending below diaphragm).
Clinical Presentation & Diagnostic Evaluation
Diagnostic Parameter Clinical Finding Pathophysiologic Basis
Pain Profile Abrupt onset, maximal severity at baseline, "tearing," "ripping," or "sharp" pain. Acute delamination of intimal-medial wall layers. Anterior chest pain suggests Type A; back/interscapular pain suggests Type B.
Blood Pressure Differential > 20 mmHg SBP difference between upper extremities. Compression or involvement of the brachiocephalic or left subclavian artery ostium by the false lumen.
Pulse Deficits Asymmetric, weak, or absent radial, carotid, or femoral pulses. Dissection flap occluding branch artery lumens.
New Heart Murmur High-pitched diastolic decrescendo murmur at right sternal border. Acute aortic regurgitation due to aortic root dilation or prolapse of intimal flap into aortic valve leaflets (Type A).
Beck's Triad Hypotension, JVD, muffled heart sounds. Retrograde rupture into pericardial sac producing acute pericardial tamponade.
Neurological Deficits Stroke symptoms, paraplegia, or altered mental status. Carotid artery dissection (stroke) or spinal artery ischemia via occlusion of intercostal/lumbar arteries (paraplegia).
Diagnostic Modalities
CT Angiography (CTA) : Gold standard for hemodynamically stable patients. Provides detailed anatomic visualization of intimal entry tear, true vs false lumen, and organ branch perfusion.
Transesophageal Echocardiography (TEE) : Ideal for hemodynamically unstable patients at the bedside or in the OR. Provides 98% sensitivity for Type A dissection and assesses acute aortic regurgitation and pericardial effusion.
Chest X-Ray : May demonstrate a widened mediastinum (>8 cm), loss of the normal aortic knob contour, or displacement of intimal calcification >5 mm.
Acute Anti-Impulse Therapy: Strict Pharmacologic Ordering
The fundamental goal of medical management in acute aortic dissection is reducing aortic shear stress, expressed mathematically as dP/dt (the rate of change of ventricular pressure over time). Decreasing heart rate and blood pressure minimizes the kinetic forces driving propagation of the false lumen. SUSPECTED / CONFIRMED AORTIC DISSECTION
- │
- ▼
- ┌──────────────────────────────────────────┐
- │ STEP 1: INITIATE IV BETA-BLOCKER FIRST │
- │ Target HR 50 - 60 bpm │
- │ Esmolol (Bolus + Drip) or Labetalol IV │
- └─────────────────────┬────────────────────┘
- │
Is HR ≤60 bpm Achieved?
- │ │
- YES ───────┘ └─────── NO
- │ │
- ▼ ▼
- Is SBP still >120 mmHg? Increase Beta-Blocker
- │ │ Re-evaluate Contraindications
- YES│ │NO (e.g., acute AR, asthma)
- ▼ ▼
- ┌──────────────────────┐ Target Reached! Maintain
- │ STEP 2: ADD IV │ Continuous ICU Monitoring
- │ VASODILATOR │
- │ Nitroprusside, │
- │ Nicardipine, or │
- │ Clevidipine │
- │ Target SBP 100-120 │
- └──────────────────────┘
- MANDATORY RULE: Beta-Blockade Prior to Vasodilation
Nurses must NEVER initiate direct vasodilators (such as Sodium Nitroprusside, Nicardipine, or Clevidipine) prior to establishing adequate intravenous beta-blockade. Administering vasodilators in isolation triggers a profound reflex sympathetic tachycardia, increasing LV contractility and dP/dt, which accelerates intimal propagation and aortic rupture.
First-Line Pharmacological Agents
Esmolol : Ultra-short-acting selective beta₁-antagonist. Loading dose: 500 mcg/kg IV over 1 minute, followed by continuous infusion at 50 mcg/kg/min, titrating up to 300 mcg/kg/min. Rapid onset (1-2 min) and short half-life (9 min) allow immediate reversal if heart block or hypotension develops.
Labetalol : Combined α₁ and non-selective β-antagonist (1:7 ratio IV). Dose: 20 mg IV slow push over 2 minutes, followed by repeat doses of 40–80 mg q10min (max 300 mg), or continuous infusion at 0.5–2.0 mg/min.
Clevidipine / Nicardipine : IV dihydropyridine calcium channel blockers added only after HR ≤ 60 bpm to reduce SBP to 100–120 mmHg.
Surgical vs. Medical Management & Aortic Aneurysms
Aortic Condition Primary Management Surgical / Interventional Indications Nursing & Post-Op Priorities
Stanford Type A Dissection Emergency Open Surgical Repair All confirmed cases immediately. Resection of tear, synthetic graft replacement, aortic valve repair/resuspension, coronary re-implantation.
Stanford Type B Dissection ICU Medical Therapy Complicated Type B: branch vessel malperfusion, intractable pain, rapid expansion, or rupture → TEVAR . Strict SBP/HR control, serial CTA imaging, monitoring leg/visceral perfusion.
Thoracic Aortic Aneurysm (TAA) Serial Imaging & BP control Diameter ≥ 5.5 cm (or ≥ 5.0 cm in Marfan syndrome), or growth > 0.5 cm/year. Maintain SBP < 120 mmHg, avoid strenuous isometric lifting, post-TEVAR spinal cord ischemia monitoring.
Abdominal Aortic Aneurysm (AAA) Serial Ultrasonography / CT Diameter ≥ 5.5 cm (men), ≥ 5.0 cm (women), or growth > 0.5 cm in 6 months. Monitor for rupture triad (abdominal pain, pulsatile mass, shock), post-EVAR endoleak monitoring.
Hypertensive Crises: Emergency vs. Urgency
A hypertensive crisis is defined by a severe elevation in blood pressure, typically Systolic BP > 180 mmHg and/or Diastolic BP > 120 mmHg.
Key Differentiating Criteria
Hypertensive Urgency : Severe BP elevation WITHOUT clinical or laboratory evidence of acute target organ damage. Treated with oral antihypertensives (Captopril, Labetalol, Clonidine) over 24 to 48 hours in an outpatient or step-down setting.
Hypertensive Emergency : Severe BP elevation WITH ongoing, life-threatening acute target organ damage. Requires immediate admission to an ICU for continuous arterial line pressure monitoring and intravenous vasoactive titration.
Manifestations of Target Organ Damage
Neurological : Hypertensive encephalopathy (headache, confusion, papilledema, seizures), acute ischemic stroke, intracranial hemorrhage.
Cardiovascular : Acute aortic dissection, acute MI/unstable angina, acute cardiogenic pulmonary edema with LV failure.
Renal : Acute Kidney Injury (AKI), hematuria, proteinuria, necrotizing arteriolosclerosis.
Ophthalmologic : Grade III/IV hypertensive retinopathy (flame hemorrhages, cotton wool spots, papilledema).
- Intravenous Antihypertensive Agents & BP Reduction Guidelines
- General BP Reduction Guideline
For most hypertensive emergencies, lower Mean Arterial Pressure (MAP) by no more than 20% to 25% within the first hour . If stable, reduce BP toward 160/100 mmHg over the next 2 to 6 hours, and gradually normalize over 24 to 48 hours. Excessive, rapid blood pressure reduction can precipitate watershed cerebral infarction, myocardial ischemia, and acute renal tubular necrosis due to shifted organ autoregulation curves.
Critical Exceptions to standard BP reduction rates
Acute Aortic Dissection : Rapid reduction of SBP to < 120 mmHg and HR to < 60 bpm within 20 minutes .
Acute Ischemic Stroke : Do NOT lower BP unless SBP > 220 mmHg or DBP > 120 mmHg, UNLESS the patient is eligible for IV thrombolysis (alteplase/tenecteplase) or mechanical thrombectomy, where the target is SBP < 185 mmHg and DBP < 110 mmHg prior to therapy.
Pheochromocytoma Crisis / Severe Preeclampsia : Rapid reduction of SBP to < 140 mmHg within the first hour.
IV Antihypertensive Agent Mechanism of Action Dose & Titration Key Nursing & Safety Considerations
Clevidipine (Cleviprex) Ultra-short-acting dihydropyridine calcium channel blocker. 1 – 2 mg/h IV; double q90sec initially; max 32 mg/h. Rapid onset (1-2 min) and offset (5-15 min). Lipid emulsion formulation (strict aseptic technique, change lines q12h, lipid intake limits).
Nicardipine (Cardene) Arterial-selective dihydropyridine calcium channel blocker. 5 mg/h IV; titrate by 2.5 mg/h q5-15min; max 15 mg/h. Excellent coronary and cerebral vasodilation; change peripheral infusion site q12h to prevent phlebitis.
Sodium Nitroprusside Direct venous and arterial vasodilator (cGMP mediated). 0.25 – 0.5 mcg/kg/min IV; max 10 mcg/kg/min. Cyanide & Thiocyanate Toxicity risk with high dose (>2 mcg/kg/min), prolonged use (>48h), or renal/hepatic impairment. Protect from light.
Fenoldopam (Corlopam) Selective dopamine D₁-receptor agonist. 0.01 – 0.3 mcg/kg/min IV titration. Promotes renal vasodilation, natriuresis, and diuresis; ideal for hypertensive emergency with acute renal failure.
Sodium Nitroprusside Toxicity Monitoring
Nitroprusside contains 44% cyanide by weight. Cyanide is converted in the liver by rhodanese (thiosulfate sulfurtransferase) into thiocyanate, excreted by the kidneys. Clinical signs of toxicity include unexplained lactic acidosis, metabolic acidosis, bright red venous blood (failure of tissue O₂ extraction), confusion, and seizures. Treat immediately with Sodium Thiosulfate or Hydroxocobalamin.